Prognoza
Średnia cena docelowa analityków wynosi 86,58 € (+36,35%). Mediana wynosi 86,58 € (+36,35%).
| Kupuj |
10 |
| Trzymaj |
2 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
RadNet beats Q2 forecasts and raises full-year guidance
RadNet reported adjusted EPS of $0.29 for Q2 2026 on revenue of $622.7m, both well above consensus estimates, and posted an adjusted EBITDA quarterly record of $99.7m. Total revenue rose 25% year over year, driven by stronger demand for advanced imaging and a 56.5% increase in digital-health revenue; ARR nearly doubled to $105.5m. The company raised its full-year targets for imaging revenue, adjusted EBITDA and free cash flow. The stock rose about 6% in after-hours trading, while management highlighted accelerated adoption of AI solutions and continued wage-pressure and integration risks. » Więcej na de.investing.com
RadNet secures $250 million loan and lowers interest costs
RadNet has amended its existing credit agreement and taken on an additional $250 million loan, which is being combined with the existing facility (totaling $1.2087 billion) and matures on April 18, 2031. Quarterly principal payments will rise from $2.4 million to about $3.1 million. RadNet plans to use the funds for acquisitions, organic growth, healthcare partnerships and general corporate purposes. The interest rate has been cut by 0.25 percentage points (choice of Term SOFR plus 2.00% or an alternate base rate plus 1.00%), and the terms of the revolving credit line were also improved, strengthening the company’s financial flexibility with a cash position of $455 million as of March 31, 2026. » Więcej na de.investing.com
DeepHealth (RadNet subsidiary) launches AI platform Reporting Pro for radiology reporting
DeepHealth, a wholly owned subsidiary of RadNet, has made Reporting Pro commercially available — an AI-powered platform for creating radiology reports that combines speech recognition, clinical AI findings, measurements, generative AI assessments, and quality assurance in a single workflow. The solution incorporates both FDA-cleared and CE-marked AI tools, can integrate with existing PACS/RIS systems, and supports all imaging modalities. RadNet is rolling out Reporting Pro across its own network, has secured initial external customers, and plans to expand into additional countries by the end of the year. » Więcej na de.investing.com
Moody's cuts rating of RadNet's senior secured bank credit facilities after $200m loan
Moody’s downgraded RadNet’s senior secured bank credit facilities from Ba3 to B1; the Corporate Family Rating remains at B1 with a stable outlook. The downgrade follows the issuance of an additional $200 million senior loan to finance acquisitions and expansion, which raises pro forma leverage from about 4.5x to around 5.0x. Moody’s cites higher fixed costs and geographic concentration as pressure points, but highlights RadNet’s strong competitive position, revenue diversification and a pro forma liquidity position of more than $600 million, and expects leverage to decline over the next 12–18 months. » Więcej na de.investing.com
RadNet beats revenue forecasts in Q1 2026, stock rises despite EPS miss
RadNet reported Q1 2026 revenue of $575.63 million versus $557.64 million expected (+3.23% surprise) with EPS of $-0.28 (forecast -$0.15). Revenue rose 22.1% year over year, adjusted EBITDA increased 36.3%, and days sales outstanding (DSO) were 29.5 days. The stock climbed 8.95% in premarket trading to $63.40 as investors reacted positively to revenue growth, digital health initiatives and acquisition contributions. RadNet maintains an upbeat outlook with FY 2026 guidance of $0.63 EPS and expected revenues of $2.45 billion. » Więcej na de.investing.com
Dane finansowe
W ostatnim kwartale RadNet osiągnęła przychody w wysokości 563,49 mln € i zysk netto w wysokości 3,67 mln €
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 563,49 mln | 26,47% |
| Zysk brutto | 75,81 mln | 22,74% |
| Zysk netto | 3,67 mln | 20,57% |
| EBITDA | 84,05 mln | 27,39% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 5 mld € |
Liczba akcji | 78,77 mln |
Maksimum/minimum z 52 tygodni | 78,23 € - 46,31 € |
| Dywidendy | Nie |
Beta | 1,40 |
C/Z (PE Ratio) | -242,22 |
PEG (PEG Ratio) | 3,65 |
C/WK (PB Ratio) | 4,84 |
C/S (PS Ratio) | 2,30 |
Profil spółki
RadNet, Inc. wraz z podmiotami zależnymi świadczy w Stanach Zjednoczonych ambulatoryjne usługi diagnostyki obrazowej. Jej usługi obejmują rezonans magnetyczny, tomografię komputerową, pozytonową tomografię emisyjną, medycynę nuklearną, mammografię, ultrasonografię, radiologię diagnostyczną, fluoroskopię oraz inne powiązane procedury, a także usługi obrazowania multimodalnego. Spółka opracowuje i sprzedaje również systemy komputerowe dla branży diagnostyki obrazowej, w tym systemy archiwizacji i komunikacji obrazów (PACS) oraz powiązane usługi; ponadto opracowuje i wdraża pakiety rozwiązań AI wspomagających interpretację obrazów przez radiologów w zakresie mammografii, a także rozwiązania AI dla raka płuc i raka prostaty. Na dzień 31 grudnia 2021 roku posiadała i zarządzała 347 ośrodkami w Arizonie, Kalifornii, Delaware, Floryda, Maryland, New Jersey i Nowym Jorku. Spółka została założona w 1981 roku i ma siedzibę w Los Angeles w Kalifornii.
| Nazwa | RadNet |
| CEO | Howard G. Berger |
| Siedziba | Los Angeles,
ca Stany Zjednoczone |
| Strona internetowa | |
| Sektor | Ochrona zdrowia |
| Branża | Ochrona zdrowia: sprzęt i produkty |
| Debiut giełdowy | 10.12.2021 |
| Pracownicy | 9060 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | RDNT |
Frankfurt | PQIA.F |
Düsseldorf | PQIA.DU |
SIX | PQIA.SW |